Clinical Trials Directory

Trials / Completed

CompletedNCT01607489

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Medical University of Graz · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT). In this pilot study the investigators investigate patients who underwent right heart catheterisation with DE-CT to determine hemodynamic parameters and control the results by other clinical investigations. The investigators expect that using this non-invasive method, parameters relevant for the diagnosis of the patients with PAH, like pulmonary blood volume, blood flow and perfusion heterogeneity, can be determined.

Detailed description

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease. It is characterized by the elevation of pulmonary arterial pressure and pulmonary vascular resistance. A remodeling of small pulmonary vessels characterized by the proliferation of the adventitia, the hypertrophy of the media and fibrosis of the intima can be observed on the microscopic level. Non-invasive techniques for hemodynamic assessment and identification of early pulmonary vascular remodeling and pulmonary hypertension have a marked practical advantage as compared to invasive right heart catheterization, however, their accuracy and reliability is not well established. In the present study the investigators examine patients who underwent right heart catheterization and are scheduled for a thorax CT with an additional dynamic contrast-enhanced DE-CT protocol and derive established parameters for the diagnosis of PAH as well as novel parameters from the CT scans. These are compared to results from the right-heart catheterization and other investigations routinely carried out on these patients.

Conditions

Interventions

TypeNameDescription
RADIATIONDual-energy computed tomography investigation1x 20ml Ultravist (370mg J/ml)3-5ml/s, 1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration

Timeline

Start date
2011-06-01
Primary completion
2017-03-01
Completion
2017-03-01
First posted
2012-05-30
Last updated
2017-07-17

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT01607489. Inclusion in this directory is not an endorsement.